The role of bispecific antibodies in relapsed/refractory multiple myeloma with renal impairment: A systematic review

This systematic review evaluated the efficacy and safety of bispecific antibodies in multiple myeloma patients with renal impairment. Analyzing data from 1,117 patients, the study found that survival outcomes and response rates were comparable to those with normal renal function. Aside from increased thrombocytopenia, safety profiles remained manageable, supporting the use of these agents in clinical practice.